Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY1R | P25929 | 1/20 | 0.62 |
| ▸ | NPY2R | P49146 | 1/20 | 0.62 |
| ▸ | NPY4R | P50391 | 1/20 | 0.62 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.62 |
| ▸ | CALCR | P30988 | 4/20 | 0.60 |
| ▸ | GLP1R | P43220 | 10/20 | 0.60 |
| ▸ | CCKBR | P32239 | 2/20 | 0.60 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.57 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.57 |
| ▸ | GIPR | P48546 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30712903 | 0.90 | CXCR4 (0.65) | NPY1RNPY2RNPY4RNPY5RCALCR | |
| SCHEMBL31182564 | 0.89 | NPY1R (0.70) | NPY1RNPY2RNPY4RNPY5RGLP1R | |
| SCHEMBL31656488 | 0.89 | NPY1R (0.66) | NPY1RNPY2RNPY4RNPY5RCALCR | |
| SCHEMBL29706258 | 0.89 | GLP1R (0.63) | NPY1RNPY2RNPY4RNPY5RCALCR | |
| SCHEMBL29706271 | 0.89 | GLP1R (0.64) | NPY1RNPY2RNPY4RNPY5RCALCR | |
| SCHEMBL30567706 | 0.89 | GLP1R (0.70) | NPY1RNPY2RNPY4RNPY5RCALCR | |
| SCHEMBL30712940 | 0.88 | GLP1R (0.68) | NPY1RNPY2RNPY4RNPY5RCALCR | |
| SCHEMBL31182837 | 0.88 | CXCR4 (0.67) | NPY1RNPY2RNPY4RNPY5RCALCR | |
| SCHEMBL29812751 | 0.88 | GLP1R (0.63) | NPY1RNPY2RNPY4RNPY5RCALCR | |
| SCHEMBL29812848 | 0.88 | GLP1R (0.64) | NPY1RNPY2RNPY4RNPY5RCALCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4677075-A2 | TARGETING CELLS IN STRESSED GROWING CONDITIONS | SNIPR Biome ApS (DK) | 2026-01-14 | — | — | EP | claimed |
| WO-2024184403-A2 | TARGETING CELLS IN STRESSED GROWING CONDITIONS | SNIPR BIOME APS (DK) | 2024-09-12 | — | — | WO | claimed |
| US-20260116929-A1 | ANTI-GRAM-NEGATIVE BACTERIAL COMPOUND | MURATA MANUFACTURING CO (JP) | 2026-04-30 | — | — | US | disclosed |
| EP-4677075-A2 | TARGETING CELLS IN STRESSED GROWING CONDITIONS | SNIPR Biome ApS (DK) | 2026-01-14 | — | — | EP | disclosed |
| US-20260002165-A1 | TARGETING CELLS IN STRESSED GROWING CONDITIONS | SNIPR BIOME APS (DK) | 2026-01-01 | — | — | US | disclosed |
| US-12428452-B2 | Anti-gram-negative bacterial compound | MURATA MANUFACTURING CO., LTD. (JP) | 2025-09-30 | — | — | US | disclosed |
| US-20250122550-A1 | METHODS AND COMPOSITIONS FOR MAKING BACTERIOCINS AND ANTIMICROBIAL PEPTIDES | SYNGULON SA (BE) | 2025-04-17 | — | — | US | disclosed |
| CN-113039196-B | Anti-Gram-negative compounds | 株式会社村田制作所 | 2025-03-18 | — | — | CN | disclosed |
| US-12234299-B2 | Peptides for inducing bacteriocin synthesis and methods to identify and/or select and/or optimize the same | SYNGULON S.A. (BE) | 2025-02-25 | — | — | US | disclosed |
| US-12195780-B2 | Methods and compositions for making bacteriocins and antimicrobial peptides | SYNGULON SA (BE) | 2025-01-14 | — | — | US | disclosed |
| WO-2024184403-A2 | TARGETING CELLS IN STRESSED GROWING CONDITIONS | SNIPR BIOME APS (DK) | 2024-09-12 | — | — | WO | disclosed |
| US-20240041944-A1 | OPTIMIZED INDIVIDUALIZED PREBIOTIC COMPOSITIONS | ISOTHRIVE LLC | 2024-02-08 | — | — | US | disclosed |
| CN-105861396-B | Marine-source bacillus antibacterial protein MD and preparation method thereof | 自然资源部第三海洋研究所 | 2023-10-13 | — | — | CN | disclosed |
| US-20230279461-A1 | METHODS AND COMPOSITIONS FOR MAKING BACTERIOCINS AND ANTIMICROBIAL PEPTIDES | SYNGULON SA (BE) | 2023-09-07 | — | — | US | disclosed |
| US-20230210916-A1 | Bacteriocin Production, Compositions and Methods of Use | ISOTHRIVE INC. | 2023-07-06 | — | — | US | disclosed |
| US-11492651-B2 | Methods and compositions for making bacteriocins and antimicrobial peptides | SYNGULON SA (BE) | 2022-11-08 | — | — | US | disclosed |
| US-11421223-B2 | Processes and host cells for genome, pathway, and biomolecular engineering | ENEVOLV, INC. (US) | 2022-08-23 | — | — | US | disclosed |
| US-11246893-B2 | Bacteriocin production, compositions and methods of use | ISOTHRIVE INC. (US) | 2022-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12428452-B2 | Anti-gram-negative bacterial compound | NIT2, BPGM, FABP2 | NPY1R 2158/4885NPY2R 1144/4885NPY4R 3346/4885 |
| US-20260002165-A1 | TARGETING CELLS IN STRESSED GROWING CONDITIONS | ATF4, BACH1, ATF1 | NPY1R 2656/4885NPY2R 3572/4885NPY4R 4562/4885 |
| US-20230210916-A1 | Bacteriocin Production, Compositions and Methods of Use | SCTR, GRPR, BMPR2 | NPY1R 109/4885NPY2R 91/4885NPY4R 103/4885 |
| US-11246893-B2 | Bacteriocin production, compositions and methods of use | SCTR, GRPR, BMPR2 | NPY1R 109/4885NPY2R 91/4885NPY4R 103/4885 |
| US-20240041944-A1 | OPTIMIZED INDIVIDUALIZED PREBIOTIC COMPOSITIONS | DDOST, STT3A, SI | NPY1R 1327/4885NPY2R 1638/4885NPY4R 965/4885 |
| US-20260116929-A1 | ANTI-GRAM-NEGATIVE BACTERIAL COMPOUND | TLL2, TMPO, BCL2L2 | NPY1R 840/4885NPY2R 382/4885NPY4R 2364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.